SURGEPAYS INC (SURG)

US86882L2043 - Common Stock

1.77  +0.04 (+2.31%)

After market: 1.77 0 (0%)

Fundamental Rating

2

SURG gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 22 industry peers in the Wireless Telecommunication Services industry. While SURG seems to be doing ok healthwise, there are quite some concerns on its profitability. SURG is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SURG has reported negative net income.
In the past year SURG has reported a negative cash flow from operations.
SURG had negative earnings in 4 of the past 5 years.
In multiple years SURG reported negative operating cash flow during the last 5 years.

1.2 Ratios

SURG has a Return On Assets of -55.17%. This is amonst the worse of the industry: SURG underperforms 95.24% of its industry peers.
With a Return On Equity value of -69.05%, SURG is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -55.17%
ROE -69.05%
ROIC N/A
ROA(3y)-7.37%
ROA(5y)-50.43%
ROE(3y)-107.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SURG has a Gross Margin of 5.20%. This is amonst the worse of the industry: SURG underperforms 95.24% of its industry peers.
In the last couple of years the Gross Margin of SURG has declined.
SURG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y78.16%
GM growth 5Y-10.03%

More info and screens

6

2. Health

2.1 Basic Checks

SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
SURG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SURG has been increased compared to 5 years ago.
The debt/assets ratio for SURG has been reduced compared to a year ago.

2.2 Solvency

SURG has an Altman-Z score of 2.23. This is not the best score and indicates that SURG is in the grey zone with still only limited risk for bankruptcy at the moment.
With an excellent Altman-Z score value of 2.23, SURG belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
A Debt/Equity ratio of 0.08 indicates that SURG is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.08, SURG belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 2.23
ROIC/WACCN/A
WACC8.19%

2.3 Liquidity

SURG has a Current Ratio of 6.24. This indicates that SURG is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 6.24, SURG belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 4.70 indicates that SURG has no problem at all paying its short term obligations.
SURG has a better Quick ratio (4.70) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 6.24
Quick Ratio 4.7

More info and screens

3

3. Growth

3.1 Past

The earnings per share for SURG have decreased strongly by -177.93% in the last year.
SURG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -40.73%.
SURG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.26% yearly.
EPS 1Y (TTM)-177.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-248.98%
Revenue 1Y (TTM)-40.73%
Revenue growth 3Y36.1%
Revenue growth 5Y55.26%
Sales Q2Q%-86.04%

3.2 Future

The Earnings Per Share is expected to decrease by -27.94% on average over the next years. This is quite bad
The Revenue is expected to grow by 6.49% on average over the next years.
EPS Next Y-205.12%
EPS Next 2Y-43.55%
EPS Next 3Y-27.94%
EPS Next 5YN/A
Revenue Next Year-56.12%
Revenue Next 2Y-17.14%
Revenue Next 3Y6.49%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SURG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SURG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SURG's earnings are expected to decrease with -27.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.55%
EPS Next 3Y-27.94%

More info and screens

0

5. Dividend

5.1 Amount

SURG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGEPAYS INC

NASDAQ:SURG (12/20/2024, 8:00:00 PM)

After market: 1.77 0 (0%)

1.77

+0.04 (+2.31%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners9.47%
Inst Owner Change3.99%
Ins Owners32.35%
Ins Owner Change3.21%
Market Cap35.68M
Analysts80
Price Target6.12 (245.76%)
Short Float %4.19%
Short Ratio0.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-496.37%
Min EPS beat(2)-824.37%
Max EPS beat(2)-168.38%
EPS beat(4)0
Avg EPS beat(4)-275.3%
Min EPS beat(4)-824.37%
Max EPS beat(4)-54.2%
EPS beat(8)4
Avg EPS beat(8)68.32%
EPS beat(12)4
Avg EPS beat(12)-231.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.15%
Min Revenue beat(2)-45.89%
Max Revenue beat(2)-2.4%
Revenue beat(4)1
Avg Revenue beat(4)-11.6%
Min Revenue beat(4)-45.89%
Max Revenue beat(4)7.36%
Revenue beat(8)1
Avg Revenue beat(8)-10.72%
Revenue beat(12)3
Avg Revenue beat(12)-8.51%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.35%
EPS NQ rev (1m)-18.42%
EPS NQ rev (3m)-225%
EPS NY rev (1m)-29.44%
EPS NY rev (3m)-82.87%
Revenue NQ rev (1m)-8.72%
Revenue NQ rev (3m)-72.85%
Revenue NY rev (1m)1.77%
Revenue NY rev (3m)-14.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS4.15
BVpS1.64
TBVpS1.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.17%
ROE -69.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.2%
FCFM N/A
ROA(3y)-7.37%
ROA(5y)-50.43%
ROE(3y)-107.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y78.16%
GM growth 5Y-10.03%
F-Score3
Asset Turnover2.01
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.24
Quick Ratio 4.7
Altman-Z 2.23
F-Score3
WACC8.19%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-177.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-248.98%
EPS Next Y-205.12%
EPS Next 2Y-43.55%
EPS Next 3Y-27.94%
EPS Next 5YN/A
Revenue 1Y (TTM)-40.73%
Revenue growth 3Y36.1%
Revenue growth 5Y55.26%
Sales Q2Q%-86.04%
Revenue Next Year-56.12%
Revenue Next 2Y-17.14%
Revenue Next 3Y6.49%
Revenue Next 5YN/A
EBIT growth 1Y-204.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-170.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.33%
OCF growth 3YN/A
OCF growth 5YN/A